|
|
|
|
|
|
|
|
|
05.08.26 - 09:49
|
Astellas Pharma Inc. Reveals Climb In Q1 Profit (AFX)
|
|
|
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) reported earnings for its first quarter that Increased, from last yearThe company's earnings came in at JPY141.828 billion, or JPY78.96 per share. Th......
|
|
|
05.08.26 - 09:31
|
Astellas Pharma Earnings Up In Q1; Guides FY27 (AFX)
|
|
|
TOKYO (dpa-AFX) - Astellas Pharma Inc. (4503.T, ALPMF, ALPMY), a pharmaceutical and life sciences company, on Wednesday reported higher net income in the first quarter compared with the previous y......
|
|
|
|
|
|
|
21.06.26 - 19:06
|
Syntax Bio Announces Expanded Series A and Leadership Appointments (Business Wire)
|
|
|
Company raises additional capital to advance Cellgorithm™ platform, develop pancreatic beta cell therapy for type 1 diabetes and strengthen leadershipCHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio's Series A to $14.4 million and total funding to over $25 million.
The expanded round builds on support from Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansueto Office, and Portal Innovations, and includes new participation from Draper Associates, Allegis Capital, LongGame, Mayo Clinic, the Illinois Department of Commerce and Economic Opportunity, Illinois Ventures, Exit Fund, Sigma Group, and Walder Ventures. Proceeds will support further advancement of the company's proprietary Cellgorithm™ platform and fund pancre...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.04.26 - 09:12
|
Astellas Pharma Inc. Profit Rises In Full Year (AFX)
|
|
|
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) announced earnings for its full year that Increased, from the same period last yearThe company's earnings came in at JPY291.535 billion, or JPY162.22......
|
|
|
21.04.26 - 12:24
|
Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy (PBR)
|
|
|
The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. It could potentially broaden the approved use,
The post Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
